21,136 Shares in NeoGenomics, Inc. (NASDAQ:NEO) Purchased by SG Americas Securities LLC

SG Americas Securities LLC acquired a new stake in NeoGenomics, Inc. (NASDAQ:NEO) in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm acquired 21,136 shares of the medical research company’s stock, valued at approximately $312,000.

Several other hedge funds have also recently modified their holdings of NEO. Blue Trust Inc. increased its position in shares of NeoGenomics by 107.2% during the second quarter. Blue Trust Inc. now owns 2,331 shares of the medical research company’s stock valued at $32,000 after acquiring an additional 1,206 shares during the last quarter. Canada Pension Plan Investment Board purchased a new stake in shares of NeoGenomics during the 2nd quarter valued at $57,000. PNC Financial Services Group Inc. raised its stake in shares of NeoGenomics by 27.0% during the 4th quarter. PNC Financial Services Group Inc. now owns 8,434 shares of the medical research company’s stock worth $136,000 after purchasing an additional 1,791 shares during the period. Banque Cantonale Vaudoise boosted its holdings in shares of NeoGenomics by 6.6% in the 1st quarter. Banque Cantonale Vaudoise now owns 15,942 shares of the medical research company’s stock worth $251,000 after buying an additional 993 shares during the last quarter. Finally, Gabelli Funds LLC bought a new position in NeoGenomics during the first quarter valued at about $283,000. Institutional investors own 98.50% of the company’s stock.

NeoGenomics Stock Performance

Shares of NEO opened at $13.56 on Friday. NeoGenomics, Inc. has a 12 month low of $12.77 and a 12 month high of $21.22. The business’s fifty day simple moving average is $15.38 and its two-hundred day simple moving average is $14.78. The company has a current ratio of 2.01, a quick ratio of 1.93 and a debt-to-equity ratio of 0.37. The company has a market cap of $1.73 billion, a price-to-earnings ratio of -20.55 and a beta of 1.19.

NeoGenomics (NASDAQ:NEO) last posted its quarterly earnings data on Monday, July 29th. The medical research company reported $0.03 EPS for the quarter. NeoGenomics had a negative return on equity of 2.72% and a negative net margin of 12.50%. The company had revenue of $164.50 million during the quarter, compared to analysts’ expectations of $161.82 million. During the same quarter in the prior year, the business earned ($0.09) earnings per share. NeoGenomics’s revenue for the quarter was up 12.0% compared to the same quarter last year. Research analysts anticipate that NeoGenomics, Inc. will post -0.21 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

NEO has been the subject of several research reports. Stephens reissued an “overweight” rating and set a $19.00 price objective on shares of NeoGenomics in a report on Tuesday, July 30th. Benchmark reissued a “buy” rating and set a $18.00 target price on shares of NeoGenomics in a report on Tuesday, September 24th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $19.00 target price on shares of NeoGenomics in a report on Wednesday, September 25th. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, NeoGenomics presently has an average rating of “Moderate Buy” and an average price target of $19.89.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.